Antiviral Drugs - Gambia | Statista Market Forecast

The Antiviral Drugs market in Gambia is expected to reach a projected revenue of US$217.80k in 2024.
It is anticipated that this revenue will demonstrate an annual growth rate (CAGR 2024-2029) of 1.77%, leading to a market volume of US$237.80k by 2029.
In comparison to other countries worldwide, United States is projected to generate the highest revenue, amounting to US$30.64bn in 2024.
The Gambia has seen a surge in demand for antiviral drugs due to the increasing prevalence of infectious diseases in the region.

Definition:
The Antiviral Drugs market includes treatments against viruses and virus-induced conditions, such as human immunodeficiency viruses (HIV), hepatitis B and C viruses (HBV and HCV), and Ebola. Therapies for the coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), are also included. HIV therapies also encompass highly active antiretroviral therapies (HAART) and post-exposure prophylaxis. In contrast to antibiotics, antivirals do not destroy the virus but rather inhibit its development.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Gilead Sciences, GlaxoSmithKline, Johnson & Johnson, AbbVie, Merck

HIV
Hepatitis B and hepatitis C
Ebola
COVID-19

Vaccines
Antibiotics
Immunosuppressants
In vitro diagnostics and rapid tests

Antiviral drugs have become increasingly important in the fight against viral infections worldwide. The Gambia is no exception, as the country has seen a growing demand for these drugs in recent years.

Customer preferences: Customers in the Gambia are increasingly seeking antiviral drugs to treat a variety of viral infections. This is due to a number of factors, including the rise of viral diseases such as HIV/AIDS, hepatitis, and influenza. Additionally, the growing awareness of the importance of antiviral drugs in treating these diseases has led to an increased demand for these products.

Trends in the market: The antiviral drugs market in the Gambia has seen significant growth in recent years, with a number of new products entering the market. One of the key trends in the market is the development of new antiviral drugs that are more effective and have fewer side effects than older drugs. Additionally, there has been a shift towards more targeted therapies, with drugs being developed that are specific to certain viral infections.

Local special circumstances: The Gambia faces a number of unique challenges when it comes to the antiviral drugs market. One of the biggest challenges is the lack of access to healthcare in many areas of the country. This has led to a situation where many people are unable to access the drugs they need, which has in turn led to a rise in the number of viral infections. Additionally, the high cost of many antiviral drugs has made them inaccessible to many people in the country.

Underlying macroeconomic factors: The Gambia is a developing country with a relatively small economy. As such, the antiviral drugs market in the country is heavily influenced by global economic trends. One of the key factors driving the market is the increasing prevalence of viral diseases worldwide. This has led to a growing demand for antiviral drugs, which has in turn led to increased investment in research and development in the sector. Additionally, the growing availability of generic drugs has made antiviral drugs more affordable and accessible to people in the Gambia and other developing countries.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.